Prothena Corp. (NASDAQ: PRTA) reported Q4 EPS of ($0.54), $0.06 better than the analyst estimate of ($0.60). Revenue for the quarter came in at $256 thousand versus the consensus estimate of $180 thousand.

• Net cash used in operating and investing activities was $14.6 million in the fourth quarter and $53.5 million for the full year 2019; quarter-end cash and restricted cash position of $378.4 million provides funding to advance a broad pipeline
• Reported interim data from Phase 1 study of PRX004 in patients with hereditary ATTR amyloidosis

“In 2019, we continued to advance our pipeline of novel investigational therapeutics towards key milestones,” said Gene Kinney, Ph.D., President and Chief Executive Officer of Prothena. “We reported interim data from our first-in-human Phase 1 study of PRX004 in patients with hereditary ATTR amyloidosis and continue to expect data from Part 1 of the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson’s disease this year. Looking ahead, we have expanded our innovative discovery and preclinical pipeline which consists of three targets under our global neuroscience collaboration with Bristol-Myers Squibb, as well as our proprietary preclinical and discovery programs that comprise our Alzheimer’s disease portfolio.”

For earnings history and earnings-related data on Prothena Corp. (PRTA) click here.